Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial is a research paper published in Communications Medicine (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Grant: HL147695
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Grant: HL139554
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Grant: HL147821
Oregon Health and Science University
Grant: Elemental Analysis Core
NHLBI NIH HHS
Grant: R01 HL049413
NHLBI NIH HHS
Grant: R01 HL147821
NHLBI NIH HHS
Grant: R01 HL139554
NHLBI NIH HHS
Grant: R44 HL147695
National Institutes of Health
Grant: 5R44HL147695-05
Antithrombotic Protein C Activator for Hemodialysis
National Institutes of Health
Grant: 5R29HL049413-02
BIOPHYSICAL STUDIES OF THROMBIN
National Institutes of Health
Grant: 5R01HL139554-08
Structural enzymology of protein C
National Institutes of Health
Grant: 5R01HL147821-07
Structural enzymology of factor V activation
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Fields of Study
Keywords
Sustainable Development Goals